Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MB 101 - Mustang Bio

Drug Profile

MB 101 - Mustang Bio

Alternative Names: IL13Rα2-specific CAR-T cells - Mustang Bio; MB-101 - Mustang Bio

Latest Information Update: 26 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator City of Hope National Medical Center
  • Developer City of Hope National Medical Center; National Cancer Institute (USA)
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Glioblastoma

Most Recent Events

  • 16 Oct 2019 MB 101 is still in phase I trial for Glioblastoma in USA (Intratumoural) (Intraventricualr) (NCT04003649)
  • 01 Oct 2019 Phase-I clinical trials in Glioblastoma (Combination therapy, Recurrent, Second-line therapy or greater) in USA (Intratumoural, Infusion) (NCT04003649)
  • 01 Oct 2019 Phase-I clinical trials in Glioblastoma (Monotherapy, Recurrent, Second-line therapy or greater) in USA (Intratumoural, Infusion) (NCT04003649)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top